Scientific American has announced the launch of worldVIEW, a publication that explores all facets of biotechnology with a global point of view. Read about the launch from one of its editorial consultants.
India's Department of Biotechnology is working to establish a National Biotechnology Regulatory Board that specifically will oversee biotech drugs and vaccines, an agency official said. The development of new guidelines for the approval of biotech medicines is under way and will be submitted to the Drug Controller General of India, which currently regulates both pharmaceuticals and biologics.
Genentech and Biogen Idec requested FDA approval for the use of Rituxan as initial or second-line treatment in combination with standard chemotherapy for patients with chronic lymphocytic leukemia. The application is supported by two clinical trials showing that the combination treatment can stall cancer progression for about 10 months.
Health Canada and the Canadian Food Inspection Agency have approved the production of Pioneer Hi-Bred's biotech soybean, which can produce high-oleic oil, for use in food and feed. The company plans to seek registration for the product in Canada next year.
Patients who no longer benefit from artery-opening surgeries showed a reduction in artery blockages within three months after receiving injections of stem cells derived from their bone marrow, Dutch physicians found. They found that the injected cells stimulated the development of new blood vessels, but they were unsure how it occurred, a study author said.
Schering-Plough will get exclusive rights to develop and commercialize a fixed combination of its anti-inflammation medication mometasone and Novartis' Foradil as part of an asset swap. The agreement also gives Novartis worldwide rights to QMF149, a combination of the company's smoker's-cough treatment QAB149 and mometasone.